Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Aleksandra Gołos, Joanna Góra-Tybor & Tadeusz Robak. (2023) Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert Opinion on Investigational Drugs 32:1, pages 53-67.
Read now
Read now
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Mia Sydenham, Robert K. Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Nigel Russell, Kathleen F. Kerr, Roland B. Walter & Mike Dennis. (2023) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia & Lymphoma 64:1, pages 250-252.
Read now
Read now
Roland B Walter. (2022) Where do we stand with radioimmunotherapy for acute myeloid leukemia?. Expert Opinion on Biological Therapy 22:5, pages 555-561.
Read now
Read now
Monia Marchetti, Luca Albertin, Giulia Limberti & Manuela Canicattì. (2022) Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. Expert Opinion on Pharmacotherapy 23:2, pages 263-272.
Read now
Read now
Articles from other publishers (23)
Jingyu Zhang, Haiting Duan, Renzhao Gui, Mingfei Wu, Liteng Shen, Yuheng Jin, Ao Pang, Xiaoli Yu, Shenxin Zeng, Bo Zhang, Nengming Lin, Wenhai Huang, Yuwei Wang, Xiaojun Yao, Jia Li, Xiaowu Dong, Yubo Zhou & Jinxin Che. (2023) Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia. European Journal of Medicinal Chemistry 262, pages 115872.
Crossref
Crossref
Xia Jiang, Ye Lin, Mengting Zhao, Youhong Li, Peipei Ye, Renzhi Pei, Ying Lu & Lei Jiang. (2023) Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia. European Journal of Pharmacology 956, pages 175957.
Crossref
Crossref
Marzieh Ramezani Farani, Maryam Sarlak, Amir Gholami, Maryam Azaraian, Maryam Moradi Binabaj, Sareh Kakavandi, Murtaza M. Tambuwala, Afshin Taheriazam, Mehrdad Hashemi & Sorayya Ghasemi. (2023) Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?. Pathology - Research and Practice 248, pages 154688.
Crossref
Crossref
Alberto Hernández-Sánchez & Lars Bullinger. (2023) Recent advances in precision medicine for acute myeloid leukemia. Current Opinion in Oncology.
Crossref
Crossref
Rafaela G.A. Costa, Suellen L.R. Silva, Ingrid R.S.B. Dias, Maiara de S. Oliveira, Ana Carolina B. da C. Rodrigues, Rosane B. Dias & Daniel P. Bezerra. (2023) Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biology 62, pages 102692.
Crossref
Crossref
Hae J. Park & Mark A. Gregory. (2023) Acute myeloid leukemia in elderly patients: New targets, new therapies. Aging and Cancer 4:2, pages 51-73.
Crossref
Crossref
Rahul S. Bhansali, Keith W. Pratz & Catherine Lai. (2023) Recent advances in targeted therapies in acute myeloid leukemia. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Jenna R. James, Johnathan Curd, Jennifer C. Ashworth, Mays Abuhantash, Martin Grundy, Claire H. Seedhouse, Kenton P. Arkill, Amanda J. Wright, Catherine L. R. Merry & Alexander Thompson. (2023) Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. International Journal of Molecular Sciences 24:4, pages 4235.
Crossref
Crossref
Tulasigeri M. Totiger, Anirban Ghoshal, Jenna Zabroski, Anya Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng & Justin Taylor. (2023) Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines 11:2, pages 641.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
205
411
.
Hui Feng, Yi Liu, Mengyao Zhang, Ruimin Liu, Jincheng Wang, Wenjuan Wang, Pengcheng He, Penghui Zhang & Fan Niu. (2022) De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy. Biochemical and Biophysical Research Communications 629, pages 152-158.
Crossref
Crossref
Nazmul Islam, Jamie S. Reuben, Justin Dale, Jon Gutman, Christine M. McMahon, Maria Amaya, Bruce Goodman, Joseph Toninato, Maura Gasparetto, Brett Stevens, Shanshan Pei, Austin Gillen, Sarah Staggs, Krysta Engel, Sarah Davis, Madelyne Hull, Elizabeth Burke, Lenny Larchick, Richard Zane, Grant Weller, Craig Jordan & Clay Smith. (2022) Machine Learning–Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clinical Cancer Informatics:6.
Crossref
Crossref
Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti & Roland B. Walter. (2022) Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia. Haematologica 107:11, pages 2752-2755.
Crossref
Crossref
Vladimir Ivanov, Su-Peng Yeh, Jiri Mayer, Lalit Saini, Ali Unal, Michael Boyiadzis, David M Hoffman, Kingston Kang, Sadiya N Addo, Wellington L Mendes & Amir T Fathi. (2022) Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncology 18:26, pages 2879-2889.
Crossref
Crossref
Xiangbo Zeng, Danlin Yao, Lian Liu, Yikai Zhang, Jing Lai, Jun Zhong, Xianfeng Zha, Yuhong Lu, Zhenyi Jin, Shaohua Chen, Yangqiu Li & Ling Xu. (2021)
Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT
+
NK cells may be related to poor outcome in acute myeloid leukemia
. Asia-Pacific Journal of Clinical Oncology 18:4, pages 456-464.
Crossref
Crossref
Tristan E. Knight, Holly Edwards, Soheil Meshinchi, Jeffrey W. Taub & Yubin Ge. (2022) “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers 14:14, pages 3398.
Crossref
Crossref
Erin M Kropp & Qing Li. (2022) Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Experimental Hematology 111, pages 13-24.
Crossref
Crossref
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman & Yongkui Jing. (2022) Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. Cell Death & Disease 13:4.
Crossref
Crossref
Gianfranco Bittar, Diana De Oliveira-Gomes & Gustavo Rivero. (2022) Advances and Future Goals in Acute Myeloid Leukaemia Therapy. Oncology & Haematology 18:2, pages 130.
Crossref
Crossref
Tristan E. Knight, Yubin Ge, Jeffrey W. Taub, Johann Hitzler & Joerg Krueger. (2021) When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3‐ITD AML. Pediatric Blood & Cancer 68:11.
Crossref
Crossref
Ling Xu, Lian Liu, Danlin Yao, Xiangbo Zeng, Yikai Zhang, Jing Lai, Jun Zhong, Xianfeng Zha, Runhui Zheng, Yuhong Lu, Minming Li, Zhenyi Jin, Sudheendra Hebbar Subramanyam, Shaohua Chen, Xin Huang & Yangqiu Li. (2021) PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow. Frontiers in Oncology 11.
Crossref
Crossref
Tristan E. Knight, Holly Edwards, Jeffrey W. Taub & Yubin Ge. (2021) MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. EBioMedicine 70, pages 103488.
Crossref
Crossref
Sridevi SurapallyDaniel G. Tenen & John A. Pulikkan. (2021) Emerging therapies for inv(16) AML. Blood 137:19, pages 2579-2584.
Crossref
Crossref